Operational Highlights Revenue grew by 44% on YoY basis, driven by growth across product segments to ₹1,286 in Q3FY22 from ₹893 in Q3FY21 Revenue from Pharma, Nutrition and Agro end use increased significantly. Most of the input cost is passed on resulting in better realisations Dow Jones sustainability index is 81% for the company and …
Total revenues for the quarter were at ₹555 Cr (3% growth QoQ). EBITDA from the quarter stood at ₹68 Cr (25% growth QoQ). EBITDA margins for the quarter were at 12.1%. PAT for the quarter was at ₹40 Cr (29% growth QoQ). Non-Ibuprofen pharma business has performed better than Q2 and contributed 17% to the …
Operational Highlights Revenues stood at ₹191.4 Cr in Q3FY22 from ₹183 Cr in Q3FY21 translating a growth of 4.6% EBITDA stood at ₹62.6 Cr with EBITDA margins at 31.5% PAT stood at ₹43.4 Cr with PAT margins at 22.6% 9MFY22 revenue split stood- Technicals + API: 72%, Formulations: 28% Profitability growth momentum continued backed by …
Operational Highlights The revenues for Q3FY22 stood at ₹929.1Cr from ₹674.7 Cr in same period previous year accounting to growth of 37.7% YoY EBITDA for the quarter stood at ₹78.2Cr translating to EBITDA margins of 8.4% PAT contracted by (-46.5%) YoY to ₹45.6 Cr in Q3FY22 from ₹85.2Cr in Q3FY21 translating to PAT margins of …
Operational Highlights Q3 results were beyond management expectations. Revenue increased by 33% from the previous quarter. EBITDA grew by 70%. 22-23% EBITDA margins are sustainable in future Reason for margin contractions in previous quarters Spending on certification from different institutes. Recently received Eco-passport certification from Hohenstein Institute, Germany Increase of technology personnel by 75% In …
Operational Highlights The revenues for the quarter stood at ₹93Cr with growth of 3.2% YoY EBITDA stood at ₹2.2Cr translating to EBITDA margins of 2.36% The company posted a loss of (-₹8 Cr) and negative PAT margins Q3-FY22 gross margins are better by 3.6% over Q2-FY22. However due to lower sales and under absorption of …
Operational Highlights Revenues from Operations stood at ₹356.86 Crores in Q3 FY2021-22 vs ₹295.66 Crores in Q3 FY2020-21. EBITDA stood at ₹61.74 Cr with EBITDA margins at 17% Q3FY22 revenue split – Specialty Contributed 60% & Generic contributed 40% Products contribution to revenues Insecticides 32% Fungicides 19% Herbicides 36% Others 13% Geography wise revenues contribution …
Operational Highlights The revenue for the quarter was ₹1748 cr it was up 41% YoY as against ₹1240 Cr in same quarter previous year EBITDA margins stood at 22% translation to EBITDA of ₹378 Cr Continued robust revenue momentum was fueled by solid growth trajectory in Phenolics In Q3 FY22, the company has achieved highest …
Operational Highlights During Q3FY20 the topline jumped by 35%. Revenue from operations stood at ₹1956 Cr from ₹1447 Cr in Q3FY21 EBITDA improved by 62% to ₹352 Cr from ₹217 Cr in Q3FY21 Finance Cost reduced by 15.4% YoY primarily driven by better working capital management Reduced net debt by roughly ₹240Cr Segment overview Chemicals …
Operational Highlights Recorded highest ever revenue and PAT in Q3 FY2022. Total revenues increased by 18% and 44% on Q-o-Q and Y-o-Y basis respectively to ₹178.2 Cr in Q3FY22. EBITDA stood at ₹76.1 Cr with EBITDA margins at 42.7%. In 9MFY22, Domestic region contributed 26% followed by 40% from China, 14% from Europe, 13% from …